X

Drug Profile

BCG 007

Alternative Names: BCG-007

Latest Information Update: 16 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing Biocytogen
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Anti-Mullerian hormone receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

16 Mar 2023 Preclinical trials in Solid tumours in China (Parenteral) (Beijing Biocytogen pipeline, March 2023)
16 Mar 2023 Beijing Biocytogen announces intention to submit IND application for solid tumours by the end of 2024 (Beijing Biocytogen pipeline, March 2023)
20 Jul 2022 Early research in Solid tumours in China (Parenteral) (Beijing Biocytogen website, July 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com